What is claimed is:

1. An isolated polynucleotide comprising a polynucleotide chosen from;

(a) a polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide chosen from: table B, E or H;

(b) a polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide chosen from: table B, E or H;

(c) a polynucleotide encoding a polypeptide having an amino sequence chosen from table B, E or H or fragments, analogs or derivatives thereof;

(d) a polynucleotide encoding a polypeptide chosen from: table B, E or H;

(e) a polynucleotide encoding a polypeptide capable of generating antibodies having binding specificity for a polypeptide having a sequence chosen from: table B, E or H,

(f) a polynucleotide encoding an epitope bearing portion of a polypeptide chosen from table B, E or H; and

(g) a polynycleotide complementary to a polynucleotide in (a), (b), (c), (d),(e) or (f).

2. The isolated polynucleotide of claim 1 wherein said polynucleotide is (a).

3. The isolated polynucleotide of claim 1 wherein said polynucleotide is (b).

4. The isolated polynucleotide of claim 1 wherein said polynucleotide is (c).

5. The isolated polynucleotide of claim 1 wherein said polynucleotide is (d).

6. The isolated polynucleotide of claim 1 wherein said polynucleotide is (e).

7. The isolated polynucleotide of claim 1 wherein said polynucleotide is (f).

8. The isolated polynucleotide of claim 1 wherein said polynucleotide is (g).

9. The isolated polynucleotide of claim 7 wherein said polynucleotide is chosen from table B.

10. The isolated polynucleotide of claim 9 wherein said epitope bearing portion is chosen from table C.

11. The isolated polynucleotide of claim 7 wherein said polynucleotide is chosen from table E.

12. The isolated polynucleotide of claim 11 wherein said epitope bearing portion is chosen from table F.

13. The polynucleotide of anyone of claims 1 to 12, wherein said polynucleotide is DNA.

14. The polynucleotide of anyone of claims 1 to 12, wherein said polynucleotide is RNA.

15. A vector comprising the polynucleotide of claim 13, wherein said DNA is operably linked to an expression control region.

16. A host cell transfected with the vector of claim 15.

17. A process for producing a polypeptide comprising culturing a host cell according to claim 16 under conditions suitable for expression of said polypeptide.

18. An isolated polypeptide comprising a member chosen from:

(a) a polypeptide having at least 70% identity to a second polypeptide having an amino acid sequence chosen from: table B, E or H;

(b) a polypeptide having at least 95% identity to a second polypeptide having an amino acid sequence chosen from: table B, E or H;

(c) a polypeptide having an amino acid sequence chosen from table B, E or H;

(d) a polypeptide having amino acid sequence chosen from: table B, E or H or fragments, analogs or derivatives thereof;

(e) a polypeptide capable of generating antibodies having binding specificity for a second polypeptide having a sequence chosen from table B, E or H;

(f) an epitope bearing portion of a polypeptide having an amino acid sequence chosen from: table B, E or H;

(g) the polypeptide of (a), (b), (c), (d), (e), or (f) wherein wherein the N-terminal Met residue is deleted; or

(h) the polypeptide of (a), (b), (c), (d), (e), or (f) wherein the secretory amino acid sequence is deleted.

19. The polypeptide of claim 18 wherein said polypeptide is (f).

20. The polypeptide of claim 19 wherein said polypeptide is chosen from table B.

21. The polypeptide of claim 20 wherein said epitope bearing portion is chosen from table C.

22. The polypeptide of claim 19 wherein said polypeptide is chosen from table E.

23. The polypeptide of claim 22 wherein said epitope bearing portion is chosen from table F.

24. A chimeric polypeptide comprising two or more polypeptides chosen from table B, E or H thereof; provided that the polypeptides are linked as to form a chimeric polypeptide.

25. A vaccine composition comprising a polypeptide according to any one of claims 18 to 24 and a pharmaceutically acceptable carrier, diluent or adjuvant.

26. A method for therapeutic or prophylactic treatment of meningitis, otitis media, bacteremia or pneumonia infection in an individual susceptible to meningitis, otitis media, bacteremia or pneumonia infection comprising administering to said individual a therapeutic or prophylactic amount of a composition according to claim 25.

27. A method for therapeutic or prophylactic treatment of streptococcal bacterial infection in an individual susceptible to streptococcal infection comprising administering to said individual a therapeutic or prophylactic amount of a composition according to claim 25.

28. A method according to claim 26, wherein said individual is a mammal.

29. A method according to claim 27, wherein said individual is a mammal

30. A method according to claim 26, wherein said individual is a human.

31. A method according to claim 27, wherein said individual is a human

32. A method according to claim 27, wherein said bacterial infection is S.pneumoniae, group A *streptococcus* (*pyogenes*), group B *streptococcus* (GBS or *agalactiae*), *dysgalactiae*, *uberis*, *nocardia* or *Staphylococcus aureus*.

33. A method according to claim 27, wherein said bacterial infection is S.pneumoniae.

34. Use of a vaccine composition according to claim 25 for the prophylactic or therapeutic treatment of Streptococcal infection in an animal susceptible to or infected with streptococcal infection comprising administering to said animal a prophylactic or therapeutic amount of the composition.

SUBSTITUTE SHEET (RULE 26)